ISIS Pharmaceuticals and Bristol-Meyers Squibb entered into license agreement to discover, develop and commercialize antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for preventing and treating cardiovascular disease. The deal would worth up to US$192 M to ISIS if specific milestones and sales targets are met.